Servier Expands Oncology Footprint

Servier India has received approval for Vorasidenib (Voranigo), adding a second rare-cancer treatment to its portfolio in the country. The targeted IDH inhibitor offers an option for patients with Grade 2 IDH-mutant glioma, a brain tumour that affects younger adults and has had limited therapeutic developments. With its earlier launch of Tibsovo® for IDH1-mutated AML and cholangiocarcinoma, Servier says its strategy in India focuses on science-led development, unmet clinical needs and widening access to approved oncology therapies. #BusinessToday #ServierIndia #Vorasidenib #Voranigo #CancerTreatment #BrainTumour #Oncology #CancerTreatmentIndia #IDHInhibitor #Tibsovo #MedicalBreakthrough #CancerCare #YoungAdultCancer #HealthcareInnovation #IndiaHealthcare ----------------------- Thank You for watching! Do not forget to Like | Comment | Share ----------------------- About the channel Watch us for the best news and views on business, stock markets, crypto currencies, consumer technology, the world of real estate, bullion, automobiles, start-ups and unicorns and personal finance. Business Today TV will also bring you all you need to know about mutual funds, insurance, loans and pension plans among others. Follow us at: Website: https://www.businesstoday.in WhatsApp: whatsapp.com/channel/0029Va4Hd309hXFCqY62yD2I Facebook:   / businesstoday   twitter:   / business_today   Instagram:   / business_today